Table 1.
Demographic and baseline clinical characteristics of participants with bipolar depression (intent-to-treat population)
| Item | Levothyroxine (n = 31) | Placebo (n = 31) | Difference |
|---|---|---|---|
| Bipolar I/II, n | 15/16 | 19/12 | Chi2 = 1.042, df = 1, p = 0.307 |
| Age, mean (SD), years | 41.8 (12.8) | 48.0 (14.2) | T = 1.8, df = 60, p = 0.07 |
| Sex, male/female, n | 14/17 | 16/15 | Chi2 = 0.258, df = 1, p = 0.611 |
| Total no. of mood episodes, mean (SD) | 8.0 (7.8) | 9.5 (9.2) | |
| Duration of illness (mean), years | 12.3 (9.7) | 18.1 (15.1) | T = 1.694, df = 52, p = 0.096 |
| Mean HASF score (SD); n = 62 | 5.9 (2.0) | 6.1 (2.4) | T = 0.351, df = 60, p = 0.727 |
| Mean State-STAI score (SD); n = 61 | 58.2 (9.5) | 57.4 (9.1) | T = − 0.347, df = 59, p = 0.727 |
| Mean Trait-STAI score (SD); n = 61 | 58.4 (11.4) | 57.9 (9.9) | T = 0.189, df = 59, p = 0.850 |
| HAMD baseline score, mean (SD) | 20.9 (3.0) | 21.4 (4.3) | T = 0.549, df = 60, p = 0.585 |
| MADRS baseline score, mean (SD) | 28.8 (5.6) | 30.3 (6.0) | T = 1.031, df = 60, p = 0.307 |
HASF Hamilton anxiety/somatization factor score, STAI State-Trait Anxiety Inventory, HAMD Hamilton Depression Rating Scale, MADRS Montgomery–Asberg Depression Rating Scale